Clinical trial
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage…
NCT00492505 · San Diego Pacific Oncology & Hematology Associates, Other · Unknown status
Key facts
| NCT number | NCT00492505 |
|---|---|
| Title | Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma |
| Official title | A Phase II Pilot Trial of Sorafenib, Tamoxifen and Cisplatin as Adjuvant Therapy for Patients With Stage III Malignant Melanoma |
| Lead sponsor | San Diego Pacific Oncology & Hematology Associates, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug, Procedure |
| Interventions | cisplatin, sorafenib tosylate, tamoxifen citrate, adjuvant therapy |
| Enrollment | 200 |
| Start date | Apr 1, 2007 |
| Primary completion | Dec 1, 2011 |
| First posted | Jun 27, 2007 |
| Last update posted | Jan 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: